{"id":11434,"date":"2024-06-26T02:42:17","date_gmt":"2024-06-26T02:42:17","guid":{"rendered":"https:\/\/economicherald.net\/?p=11434"},"modified":"2024-06-26T02:42:17","modified_gmt":"2024-06-26T02:42:17","slug":"asx-health-stocks-cleo-gains-fda-momentum-for-its-ovarian-cancer-detection-tech","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=11434","title":{"rendered":"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech"},"content":{"rendered":"

Cleo commences FDA process<\/p>\n

Cleo Diagnostics (ASX:COV)<\/a> has announced significant progress in advancing its regulatory strategy for its pre-surgical triage test designed to detect ovarian cancer.<\/p>\n

Recently, Cleo conducted an initial pre-submission meeting with the US FDA.<\/p>\n

During this meeting, Cleo presented its comprehensive submission framework and outlined its clinical plan for the ovarian cancer detection blood test.<\/p>\n

The interaction with the FDA was highly constructive, Cleo said, with the regulator providing positive feedback on Cleo\u2019s approach.<\/p>\n

This feedback not only validates Cleo\u2019s strategy but also enhances confidence in its clinical trial designs aligning with FDA expectations.<\/p>\n

Cleo believes such early engagements are pivotal in shaping its pathway towards gaining regulatory approval in the US, particularly through the 510(k) application pathway aimed at achieving \u201csubstantial equivalence\u201d to existing predicate devices.<\/p>\n

Cleo has also successfully obtained Institutional Review Board (IRB) approvals in both the US and Australia, which are essential for ensuring compliance of clinical trials.<\/p>\n

With these approvals in place, Cleo is now moving forward with formalising trial site contracts and preparing for patient recruitment.<\/p>\n

The international arm of the clinical trial will be overseen by Lindus Health<\/em>, a respected Contract Research Organization (CRO) based in the US.<\/p>\n

Cleo says it is now strategically placed to potentially expedite the timeline towards FDA application submission.<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Imricor expands into Hungary<\/h2>\n

Imricor Medical Systems (ASX: IMR)<\/a><\/strong> continues to expand its global footprint with a milestone in Hungary.<\/p>\n

Semmelweis University<\/strong> in Budapest has chosen Imricor to supply and install its iCMR electrophysiology system, becoming the first hospital in Hungary to adopt this technology for MRI-guided ablation procedures.<\/p>\n

The procurement included Imricor\u2019s Advantage-MR EP Recorder\/Stimulator and complementary capital devices like the Osypka HAT-500 RF Ablation Generator, and NordicNeuroLab in-room monitors.<\/p>\n

Additionally, the purchase covers consumables essential for the initial 15 procedures.<\/p>\n

The hospital anticipates commencing procedures in early Q4 under the guidance of Imricor\u2019s specialised medical team.<\/p>\n

\u201cThe tender process is sometimes required at new sites, but we know that only Imricor can bid on an \u2018iCMR electrophysiology system\u2019 because we are the only company in the world that makes one,\u201d said Steve Wedan, Chair and CEO of Imricor.<\/p>\n

\u201cWith the tender process now behind us, we look forward to installing our iCMR lab equipment and commencing procedures with the world-class medical team at Semmelweis.\u201d<\/p>\n

\u00a0<\/p>\n

Race Oncology confirms RC220 \u2018s safety<\/h2>\n

Meanwhile, Race Oncology (ASX:RAC)<\/a><\/strong> reported the successful completion of the Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for RC220 bisantrene<\/strong>, a key formulation designed for peripheral intravenous (IV) infusion in oncology treatment.<\/p>\n

Conducted by Attentive Science and Agilex Biolabs, these studies confirmed RC220 bisantrene\u2019s excellent safety profile, essential for progressing to human clinical trials slated for the second half of 2024.<\/p>\n

Results showed no unexpected toxicities, with all observed effects reversible after a recovery period.<\/p>\n

Importantly, RC220 bisantrene exhibited no adverse reactions at infusion sites, distinguishing it from previous formulations requiring central line administration.<\/p>\n

These findings are pivotal as Race Oncology prepares to advance RC220 bisantrene into Phase 1 clinical trials in multiple countries, including an Investigational New Drug (IND) application with the US FDA in 2025.<\/p>\n

\u201cReceiving clear confirmation of the safety of RC220 bisantrene in these studies and identifying a suitable starting dose for our upcoming trial is another major milestone in bringing our new drug product to cancer patients,\u201d said Race Chief Executive Officer, Dr Daniel Tillett.<\/p>\n

\u00a0<\/p>\n

At Stockhead we tell it like it is. While Race Oncology and Imricor Medical Systems are Stockhead advertisers, they did not sponsor this article.<\/em><\/p>\n

The post ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Cleo commences FDA process Cleo Diagnostics (ASX:COV) has announced significant progress in advancing its regulatory strategy for its pre-surgical triage test designed to detect ovarian [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":11435,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-11434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=11434\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Cleo commences FDA process Cleo Diagnostics (ASX:COV) has announced significant progress in advancing its regulatory strategy for its pre-surgical triage test designed to detect ovarian [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=11434\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-26T02:42:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech\",\"datePublished\":\"2024-06-26T02:42:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434\"},\"wordCount\":618,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=11434\",\"name\":\"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg\",\"datePublished\":\"2024-06-26T02:42:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=11434\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11434#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=11434","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech - Economic Herald","og_description":"Cleo commences FDA process Cleo Diagnostics (ASX:COV) has announced significant progress in advancing its regulatory strategy for its pre-surgical triage test designed to detect ovarian [more...]","og_url":"https:\/\/economicherald.net\/?p=11434","og_site_name":"Economic Herald","article_published_time":"2024-06-26T02:42:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=11434#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=11434"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech","datePublished":"2024-06-26T02:42:17+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=11434"},"wordCount":618,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=11434#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=11434","url":"https:\/\/economicherald.net\/?p=11434","name":"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=11434#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=11434#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg","datePublished":"2024-06-26T02:42:17+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=11434#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=11434"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=11434#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Cleo-commences-FDA-process.-Picture-Getty-Hr52ry.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=11434#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/11434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11434"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/11434\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/11435"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}